Icogenex Bioincubator

03/05/2026

We are excited about our rebrand and new website. Still providing Seattle’s most flexible and best equipment lab space for small and start up companies. Come check it out.

More than a Bench A biotech incubator in Seattle where life science companies launch, grow, and scale. About Since 2002, Icogenex has incubated nearly 100 biotech companies. As Seattle's best-equipped and most flexible space for your growing life science business, we provide a full-service, research...

04/24/2023

Icogenex Bioincubator is excited to be attending LSINW 2023 and presenting in the Entrepreneurial Forum on Wednesday. Hope to see you there.

12/06/2016

Oculus is now Sonoma Pharmaceuticals!

Oculus Innovative Sciences Announces Corporate Name Change to Sonoma Pharmaceuticals, Inc. and New NASDAQ Ticker Symbol to Better Align with Dermatology Focus

PETALUMA, CA — (December 5, 2016) —Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced that on December 6, 2016, it will officially change the name of the company to Sonoma Pharmaceuticals, Inc. In conjunction with the name change, the company’s ticker symbol listed on the NASDAQ will change from OCLS to SNOA (warrants SNOAW), effective December 6, 2016. The company’s new web site will be www.sonomapharma.com.

“We are pleased to align our corporate name and identity with our strategic initiative as a specialty pharmaceutical company focused on the high-margin U.S. dermatology market,” said Jim Schutz, CEO of Sonoma Pharmaceuticals. "

The Seattle crew form Sonoma Pharmaceuticals at Icogenex Bioincubator

10/20/2016

10/20/2016

Just Biotherapeutics develops technology to make it easier and cheaper to manufacture drugs that treat infectious diseases.

06/15/2016

Congratulations to Alpine Immune Sciences, a current tenant at Icogenex Bioincubator.

Alpine Immune Sciences will use the funds to create therapies that treat both cancer and autoimmune disorders.

05/18/2016

We are excited to see this news about PhaseRx!
They were a tenant at Icogenex Bioincubator from 2008-2010.

Seattle biotechnology company PhaseRx said Tuesday that it priced its initial public offering of 3.7 million shares of stock at $5 a share, for a total offering of $18.5 million before underwriting discounts and commissions.

04/27/2016

Acucela Inc., based at the Icogenex Biocubator from 2002-2006, enters into a technology license agreement with the University of Manchester. Congratulations Acucela!

Hundreds of thousands of people worldwide, who have a disease that can lead to blindness, could have their sight restored after The University of Manchester entered into a technology license with Seattle-based company Acucela Inc.

04/08/2016

PolyDrop, a current tenant at Icogenex Bioincubator, received a $750K NSF SBIR Phase II Award for development and scale-up of DiStart and DiCorr products.

This Small Business Innovation Research Phase II project aims to continue the development of a family ofnew nanostructured conductive additives for use in high-performance coatings and composite resins.

03/31/2016

Icogenex Bioincubator rents lab and office space, including use of equipment, amenities, and services at no additional charge, to startup and small biotech companies in the Seattle area.